Bausch Health Companies and KKR announced that Bausch Receivables Funding has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health. Bausch Health expects to utilize the proceeds from the facility for general corporate purposes. The facility provides access to additional liquidity for a term of approximately five years. Houlihan Lokey, Inc. acted as the Company’s financial advisor. Finacity Corporation acted as the administrator for the program, providing analytic and execution support, and is responsible for ongoing program administration and reporting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHC:
- Bausch + Lomb price target raised to $23 from $19 at BofA
- Bausch + Lomb acquisition of Xiidra a positive, says Barclays
- BLCO Expands Dry Eye Disease Portfolio with Acquisition of Xiidra from Novartis
- Bausch Health’s Bausch + Lomb to acquire Novartis’ XIIDRA
- AutoZone upgraded, SoFi downgraded: Wall Street’s top analyst calls